Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer

LIMITing tumours with an immunogenic lncRNA

Nature Cell Biology volume 23, pages 443–445 (2021)Cite this article

Subjects

Overcoming immune resistance mechanisms in patients with cancer is critical for successful immunotherapy. A new study now identifies LIMIT as an immunogenic long non-coding RNA (lncRNA) that intrinsically regulates anti-tumour immune responses, thereby highlighting the therapeutic potential of targeting lncRNAs to improve the outcome of cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: LncRNAs modulate antitumour immune responses.

References

  1. Frankish, A. et al. Nucleic Acids Res. 47, D766–D773 (2019).

    Article  CAS  Google Scholar 

  2. Schmitt, A. M. & Chang, H. Y. Cancer Cell 29, 452–463 (2016).

    Article  CAS  Google Scholar 

  3. Huarte, M. Nat. Med. 21, 1253–1261 (2015).

    Article  CAS  Google Scholar 

  4. Gaopeng, L. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-021-00672-3 (2021).

  5. Hezroni, H. et al. Cell Reports 11, 1110–1122 (2015).

    Article  CAS  Google Scholar 

  6. Hu, Q. et al. Nat. Immunol. 20, 835–851 (2019).

    Article  CAS  Google Scholar 

  7. Wang, Q. M., Lian, G. Y., Song, Y., Huang, Y. F. & Gong, Y. Life Sci. 231, 116335 (2019).

    Article  CAS  Google Scholar 

  8. Gil, N. & Ulitsky, I. Nat. Rev. Genet. 21, 102–117 (2020).

    Article  CAS  Google Scholar 

  9. Chen, Y. G., Satpathy, A. T. & Chang, H. Y. Nat. Immunol. 18, 962–972 (2017).

    Article  CAS  Google Scholar 

  10. Zhang, L., Xu, X. & Su, X. Mol. Cancer 19, 48 (2020).

    Article  Google Scholar 

  11. Carpenter, S. et al. Science 341, 789–792 (2013).

    Article  CAS  Google Scholar 

  12. Kalbasi, A. & Ribas, A. Nat. Rev. Immunol. 20, 25–39 (2020).

    Article  CAS  Google Scholar 

  13. Hou, J. et al. J. Immunother. Cancer 9, e001819 (2021).

    Article  Google Scholar 

  14. Tawbi, H. et al. J. Clin. Oncol. 36, TPS9596 (2018).

    Article  Google Scholar 

  15. Ribas, A. et al. Nat. Commun. 11, 6262 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology and Biochemistry, University of Houston, Houston, TX, USA

    Jiakai Hou & Weiyi Peng

Authors
  1. Jiakai Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiyi Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weiyi Peng.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hou, J., Peng, W. LIMITing tumours with an immunogenic lncRNA. Nat Cell Biol 23, 443–445 (2021). https://doi.org/10.1038/s41556-021-00682-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-021-00682-1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer